0 AGO4: a potential new universal target for antiviral therapeutics
A team of researchers have uncovered a protein, AGO4, which may have the potential to be used as a therapeutic target to universally increase protection against viral pathogens.
Browsing: Basic > Drug Development
0 A peek behind the paper – Blake Max on HIV integrase inhibitors
Take a look behind the scenes of a recent Future Virology article, entitled ‘Update on HIV integrase inhibitors for the treatment of HIV’, as we ask the authors about these drugs for HIV treatment and the future of this field.
0 FDA approves Merck & Co.’s Ebola vaccine Ervebo: January’s industry headlines
Take a look at the industry headlines from the last 2 months, including the FDA approval of Ebola vaccine Ervebo,…
0 New compound reverses HIV latency in macaque models
Recently, a research collaboration has managed to reverse HIV latency in infected CD4+ T cells in mouse and macaque models, exposing them to the body’s immune response.
0 WHO prequalifies Ebola vaccine: November’s industry headlines
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
2 Harnessing RNA sensors inhibits growth of tuberculosis bacterium
New research indicates that harnessing RNA sensors could allow human cells to be more attuned to killing tuberculosis, presenting an effective means for controlling the spread of the disease.
0 US FDA approves first siderophore antibiotic, cefiderocol (Fetroja)
The US FDA has approved cefiderocol (Fetroja), a siderophore cephalosporin that inhibits bacterial cell wall synthesis. Fetroja is the first approved antibiotic that functions as a siderophore.
0 Phage therapy: two paths to approval
Discover more about the two routes phage therapy could take, the standardized drug approach and the personalized medicine approach, and whether either could make it to the clinic.
0 Pneumonia, ICU patients and potential treatments – an interview with Keith Kaye
In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
2 Bacteriophage: alternative medicine or an evidence-based alternative?
Bacteriophage have been touted as the solution for antibiotic resistant microbes, why are they not being used in mainstream medicine?
